Workflow
募投项目进度调整
icon
Search documents
善水科技:年产61000吨氯代吡啶项目延期至2026年12月31日
Xin Lang Cai Jing· 2025-12-15 10:43
善水科技公告,公司于2025年12月12日召开第三届董事会第二十一次会议,审议通过了《关于调整部分 募投项目计划进度的议案》,同意将募集资金投资项目达到预定可使用状态日期延长至2026年12月31 日。此次调整不改变募集资金用途,未改变募集资金的投向及项目实施方式,不会对公司正常经营产生 重大不利影响。 ...
上海昊海生物科技股份有限公司 关于使用暂时闲置募集资金进行现金管理的公告
Core Viewpoint - The company plans to utilize temporarily idle raised funds for cash management, ensuring safety and liquidity while aiming to enhance returns for the company and its shareholders [2][3][20]. Investment Overview - **Investment Purpose**: The objective is to improve the efficiency of raised funds, ensuring that the use of these funds does not affect project construction and safety, while increasing returns for the company and shareholders [3]. - **Investment Amount**: The company intends to use up to RMB 300 million (including principal) for cash management, with a validity period of 12 months from the board's approval [4][16]. - **Source of Funds**: The cash management funds will come from temporarily idle raised funds from the company's initial public offering in 2019 [5]. Fund Management - **Fund Usage**: The raised funds from the IPO amounted to RMB 1,588.29 million, with a net amount of RMB 1,529.27 million after deducting issuance costs. All funds have been deposited in a special account approved by the board [6][24]. - **Investment Projects**: The raised funds are allocated for international pharmaceutical R&D and working capital, with adjustments made to project timelines as necessary [7][23]. Investment Methodology - **Investment Products**: The company will invest in low-risk, liquid, and capital-protected products such as agreement deposits, notice deposits, time deposits, large certificates of deposit, and income certificates, with a maximum term of 12 months [10][16]. - **Implementation**: The board authorizes the management to make investment decisions within the approved limits and timeframe, with the finance department responsible for execution [11]. Cash Management Returns - **Return Allocation**: Earnings from cash management will be prioritized to cover any shortfalls in project investment amounts and will be managed according to regulatory requirements [12]. Recent Cash Management Situation - **Recent 12-Month Overview**: The authorization for cash management is valid for 12 months, allowing for rolling use of funds within the specified limits [13][14]. Board Approval Process - **Approval Details**: The board approved the cash management proposal on November 7, 2025, confirming that it would not affect the normal operation of the company's investment plans [15][21]. Impact on Company - **Operational Impact**: The planned cash management will not affect the normal operations or project funding of the company, and it aims to generate additional investment returns [20][29].
上海昊海生物科技股份有限公司关于使用暂时闲置募集资金进行现金管理的公告
Core Viewpoint - The company plans to utilize temporarily idle raised funds for cash management to enhance fund efficiency and generate additional returns for the company and its shareholders [3][9][18]. Investment Overview - **Investment Purpose**: The aim is to improve the efficiency of raised fund usage while ensuring that it does not affect the construction and use of the raised fund projects [3]. - **Investment Amount**: The company intends to use up to RMB 300 million (including principal) for cash management, with a validity period of 12 months from the board's approval [4][14]. - **Source of Funds**: The funds for this cash management initiative come from the temporarily idle raised funds from the company's initial public offering in 2019 [5]. Investment Details - **Investment Products**: The company will invest in low-risk, liquid, and capital-protected financial products, including but not limited to agreement deposits, notice deposits, time deposits, large certificates of deposit, and income certificates [2][10]. - **Implementation Method**: The board authorizes the management to make investment decisions within the approved limits and timeframe, with the finance department responsible for execution [11][14]. Recent Cash Management Situation - The company has previously authorized cash management of up to RMB 400 million, with the latest authorization allowing for up to RMB 300 million [13][26]. Impact on the Company - The planned cash management will not affect the normal operation of the company's main business or the normal turnover of funds, and it aims to generate investment returns for the company and its shareholders [18][20]. Sponsor's Verification Opinion - The sponsor, UBS Securities, has confirmed that the cash management initiative has been approved by the board and complies with relevant laws and regulations, ensuring that it does not alter the intended use of raised funds [19][20].
一博科技董事会通过两项关键议案:募投项目延期一年至2026年11月达预定状态 2025年三季报获审议确认
Xin Lang Cai Jing· 2025-10-28 09:49
Core Viewpoint - Shenzhen Yibo Technology Co., Ltd. announced adjustments to its fundraising project implementation schedule and confirmed its Q3 2025 report, which are significant for short-term capacity planning and compliance with information disclosure regulations [1][3][4] Meeting Details - The board meeting was held on October 28, 2025, with all 8 directors present, and the meeting procedures complied with relevant laws and regulations [2] Proposal One: Fundraising Project Delay - The board approved a one-year delay in the fundraising project, now set to reach operational status by November 2026, to align production capacity with market demand and avoid premature investment waste [3] - The delay is attributed to the slower-than-expected procurement and installation of production equipment, despite the completion of infrastructure work [3] - The board expressed confidence in the industry outlook, anticipating a gradual recovery in market demand [3] Proposal Two: Q3 2025 Report Confirmation - The board confirmed the Q3 2025 report, ensuring compliance with legal and regulatory requirements, and affirmed the accuracy and completeness of the report [4] - The report was prepared in accordance with the requirements of the China Securities Regulatory Commission and Shenzhen Stock Exchange, with no violations of confidentiality found during the process [4] - The board takes responsibility for the report's content, ensuring no false statements or significant omissions [4]